medgenМедицинская генетикаMedical Genetics2073-7998Publishing House «Genius Media» LLC10.25557/2073-7998.2024.01.52-59medgen-2410Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHАссоциация полиморфизмов H19 с риском развития рака молочной железы: мета-анализAssociation of H19 polymorphism with breast cancer risk: a meta-analysisТимофееваС. В.TimofeevaS. V.

344037

344037

63, 14th line st.

Rostov-on-Don

СитковскаяА. О.SitkovskayaA. O.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

ФилипповаС. Ю.FilippovaS. Yu.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

ЧембароваТ. В.ChembarovaT. V.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

НовиковаИ. А.NоvikovaI. A.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

КитО. И.KitO. I.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

ВащенкоЛ. Н.VashchenkoL. N.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

БабиеваС. М.BabievaS. M.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

БакулинаС. М.BakulinaS. M.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

КечеджиеваЭ. Э.KechedzhievaE. E.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

АндрейкоЕ. А.AndreikoE. A.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

МезенцевС. С.MezentsevS. S.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

ПржедецкийЮ. В.PrzhedetskyYu. V.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

КолесниковЕ. Н.KolesnikovE. N.

344037

14-я линия, д. 63

Ростов-на-Дону

344037

63, 14th line st.

Rostov-on-Don

ФГБУ Национальный медицинский исследовательский центр онкологии Минздрава РоссииРоссияNational Medical Research Centre for OncologyRussian Federation2024050320242315259Copyright © Тимофеева С.В., Ситковская А.О., Филиппова С.Ю., Чембарова Т.В., Новикова И.А., Кит О.И., Ващенко Л.Н., Бабиева С.М., Бакулина С.М., Кечеджиева Э.Э., Андрейко Е.А., Мезенцев С.С., Пржедецкий Ю.В., Колесников Е.Н., 20242024Тимофеева С.В., Ситковская А.О., Филиппова С.Ю., Чембарова Т.В., Новикова И.А., Кит О.И., Ващенко Л.Н., Бабиева С.М., Бакулина С.М., Кечеджиева Э.Э., Андрейко Е.А., Мезенцев С.С., Пржедецкий Ю.В., Колесников Е.Н.Timofeeva S.V., Sitkovskaya A.O., Filippova S.Y., Chembarova T.V., Nоvikova I.A., Kit O.I., Vashchenko L.N., Babieva S.M., Bakulina S.M., Kechedzhieva E.E., Andreiko E.A., Mezentsev S.S., Przhedetsky Y.V., Kolesnikov E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medgen-journal.ru/jour/article/view/2410

   Мета-анализ был направлен на оценку связи между полиморфизмами rs2107425, rs2839698, rs217727, rs3741219 гена H19 и риском развития рака молочной железы. Поиск публикаций проводили в базах данных Google Scholar и PubMed за последние 13 лет. Ассоциацию оценивали по статистическим критериям отношения шансов (ОШ) с 95 % доверительным интервалом (ДИ). Для проведения мета-анализа использовали программное обеспечение RevMan (Cochrane Collaboration, 5.3. Копенгаген). Для оценки связи четырех полиморфизмов rs2107425, rs2839698, rs217727, rs3741219 с риском развития рака молочной железы в мета-анализ были включены 9 исследований случай-контроль с общей выборкой из 6572 пациентов с раком молочной железы и 6968 доноров в контрольной группе. В результате исследования мы наблюдали связь между rs2839698 H19 и риском развития рака молочной железы в аллельной модели (ОШ = 1,33, 95 % ДИ: 1,00- 1,76, Pz = 0,005, Pi2 = <0.00001). Кроме того, в рецессивной модели риск развития рака молочной железы также был ассоциирован с мутантным аллелем rs2839698 (ОШ = 1,33, 95 % ДИ: 1,03-1,71, Pz = 0,03, Pi2 = 0,05). Значимых ассоциаций с риском развития рака молочной железы полиморфизмов rs2107425, rs217727, rs3741219 не обнаружили. Настоящий метаанализ показал, что полиморфизм rs2839698 H19 ассоциирован с риском развития рака молочной железы.

   The meta-analysis was aimed to evaluate the association between polymorphisms rs2107425, rs2839698, rs217727, rs3741219 of the H19 gene and the risk of developing of breast cancer. Publications were searched in the Google Scholar and PubMed databases until August 2023. The association was assessed by statistical odds ratio (OR) criteria with a 95% confidence interval (CI). RevMan software (Cochrane Collaboration, 5.3. Copenhagen) was used for the meta-analysis. To assess the association of polymorphisms rs2107425, rs2839698, rs217727, rs3741219 with the risk of developing breast cancer, 9 case-control studies with a total sample of 6572 patients with breast cancer and 6968 donors in the control group were included in the meta-analysis. As a result of the study, we observed an association between rs2839698 H19 and the risk of developing breast cancer when calculating the allelic model (OR = 1.33, 95 % CI: 1.00-1.76, Pz = 0.005, Pi2 = < 0.00001). In addition, analysis of the recessive model also showed that the risk of developing breast cancer was significantly associated in individuals with a mutation in the polymorphic allele rs2839698 (OR = 1.33, 95 % CI: 1.03-1.71, Pz = 0.03, Pi2 = 0.05). When calculating genetic models for the rs2107425, rs217727, rs3741219 polymorphisms, no statistically significant associations with the risk of developing breast cancer were found. The present meta-analysis showed that the H19 rs2839698 polymorphism associated with the risk of breast cancer.

H19длинные некодирующие РНКрак молочной железымета-анализrs2107425rs2839698rs217727rs3741219H19long non-coding RNAsbreast cancermeta-analysisrs2107425rs2839698rs217727rs3741219Исследование проведено без спонсорской поддержкиThe study was performed without external fundingReferencesSung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660Yuan Y., Wang Y., Niu X. et al. Association of lncRNA H19 polymorphisms with cancer susceptibility: An updated meta-analysis based on 53 studies. Frontiers in genetics. 2022;(13):1051766. doi: 10.3389/fgene.2022.1051766Yuan Y., Wang Y., Niu X. et al. Association of lncRNA H19 polymorphisms with cancer susceptibility: An updated meta-analysis based on 53 studies. Frontiers in genetics. 2022;(13):1051766. doi: 10.3389/fgene.2022.1051766Taniue K., Akimitsu N.. The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci. 2021;22(2):632. doi: 10.3390/ijms22020632Taniue K., Akimitsu N.. The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci. 2021;22(2):632. doi: 10.3390/ijms22020632Ghahramani Almanghadim H., Ghorbian S., Khademi N.S. et al. New Insights into the Importance of Long Non-Coding RNAs in Lung Cancer: Future Clinical Approaches. DNA and cell biology. 2021;40(12):1476–1494. doi: 10.1089/dna.2021.0563Ghahramani Almanghadim H., Ghorbian S., Khademi N.S. et al. New Insights into the Importance of Long Non-Coding RNAs in Lung Cancer: Future Clinical Approaches. DNA and cell biology. 2021;40(12):1476–1494. doi: 10.1089/dna.2021.0563Kallen A.N., Zhou X.B., Xu J. et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Molecular cell. 2013;52(1):101–112. doi: 10.1016/j.molcel.2013.08.027Kallen A.N., Zhou X.B., Xu J. et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Molecular cell. 2013;52(1):101–112. doi: 10.1016/j.molcel.2013.08.027Yoshimizu T., Miroglio A., Ripoche M.A. et al. The H19 locus acts in vivo as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(34):2417–12422. doi: 10.1073/pnas.0801540105Yoshimizu T., Miroglio A., Ripoche M.A. et al. The H19 locus acts in vivo as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(34):2417–12422. doi: 10.1073/pnas.0801540105Zhang L., Yang F., Yuan J.H. et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577–586. doi: 10.1093/carcin/bgs381Zhang L., Yang F., Yuan J.H. et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577–586. doi: 10.1093/carcin/bgs381Moher D., Shamseer L., Clarke M. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1Moher D., Shamseer L., Clarke M. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1Barnholtz-Sloan J.S., Shetty P.B., Guan X. et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis. 2010;31(8):1417–1423. doi: 10.1093/carcin/bgq128Barnholtz-Sloan J.S., Shetty P.B., Guan X. et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis. 2010;31(8):1417–1423. doi: 10.1093/carcin/bgq128Butt S., Harlid S., Borgquist S. et al. Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC research notes. 2012;(5):414. URL: https://www.researchgate.net/publication/230621915_Genetic_predisposition_parity_age_at_first_childbirth_and_risk_for_breast_cancerButt S., Harlid S., Borgquist S. et al. Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC research notes. 2012;(5):414. URL: https://www.researchgate.net/publication/230621915_Genetic_predisposition_parity_age_at_first_childbirth_and_risk_for_breast_cancerGong W.J., Yin J.Y., Li X.P. et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(6):8349–8358. doi: 10.1007/s13277-015-4497-5Gong W.J., Yin J.Y., Li X.P. et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(6):8349–8358. doi: 10.1007/s13277-015-4497-5Xia Z., Yan R., Duan F. et al. Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population. Medicine. 2016;95(7):e2771. doi: 10.1097/MD.0000000000002771Xia Z., Yan R., Duan F. et al. Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population. Medicine. 2016;95(7):e2771. doi: 10.1097/MD.0000000000002771Hassanzarei S., Hashemi M., Sattarifard H. et al. Genetic polymorphisms in long noncoding RNA H19 are associated with breast cancer susceptibility in Iranian population. Meta Gene. 2017 Dec;(14):1-5. doi: 10.2147/OTT.S127962Hassanzarei S., Hashemi M., Sattarifard H. et al. Genetic polymorphisms in long noncoding RNA H19 are associated with breast cancer susceptibility in Iranian population. Meta Gene. 2017 Dec;(14):1-5. doi: 10.2147/OTT.S127962Lin Y., Fu F., Chen Y. et al. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. OncoTargets and therapy. 2017;(10):4369–4378. doi: 10.2147/OTT.S127962Lin Y., Fu F., Chen Y. et al. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. OncoTargets and therapy. 2017;(10):4369–4378. doi: 10.2147/OTT.S127962Cui P., Zhao Y., Chu X. et al. SNP rs2071095 in LincRNA H19 is associated with breast cancer risk. Breast cancer research and treatment. 2018;171(1):161–171. URL: https://link.springer.com/article/10.1007/s10549-018-4814-yCui P., Zhao Y., Chu X. et al. SNP rs2071095 in LincRNA H19 is associated with breast cancer risk. Breast cancer research and treatment. 2018;171(1):161–171. URL: https://link.springer.com/article/10.1007/s10549-018-4814-yAbdollahzadeh S., Ghorbian S. Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. Journal of clinical laboratory analysis. 2019;33(3):e22826. doi: 10.1002/jcla.22826Abdollahzadeh S., Ghorbian S. Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. Journal of clinical laboratory analysis. 2019;33(3):e22826. doi: 10.1002/jcla.22826Safari M.R., Mohammad Rezaei F., Dehghan A. et al. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in Iranian population. Gene. 2019;(701):121–124. doi: 10.1016/j.gene.2019.03.036Safari M.R., Mohammad Rezaei F., Dehghan A. et al. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in Iranian population. Gene. 2019;(701):121–124. doi: 10.1016/j.gene.2019.03.036Li W., Jiang X., Jin X. et al. Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction. Medicine (Baltimore). 2020 Apr;99(15):e19322. doi: 10.1097/MD.0000000000019322Li W., Jiang X., Jin X. et al. Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction. Medicine (Baltimore). 2020 Apr;99(15):e19322. doi: 10.1097/MD.0000000000019322Kit O..I, Timofeeva S.V., Sitkovskaya A.O. et al. Biobank of the “National Medical Research Centre for Oncology” as a resource for conducting research in the field of personalized medicine. Modern Oncology. 2022; (24):6-11. doi: 10.26442/18151434.2022.1.201384Kit O..I, Timofeeva S.V., Sitkovskaya A.O. et al. Biobank of the “National Medical Research Centre for Oncology” as a resource for conducting research in the field of personalized medicine. Modern Oncology. 2022; (24):6-11. doi: 10.26442/18151434.2022.1.201384Chen L., Zhang S. Long noncoding RNAs in cell differentiation and pluripotency. Cell and tissue research. 2016;366(3):509–521. doi: 10.1007/s00441-016-2451-5Chen L., Zhang S. Long noncoding RNAs in cell differentiation and pluripotency. Cell and tissue research. 2016;366(3):509–521. doi: 10.1007/s00441-016-2451-5Gao Y., Liu Y., Du L. et al. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Medical oncology (Northwood, London, England). 2015;32(1):362. doi: 10.1007/s12032-014-0362-4Gao Y., Liu Y., Du L. et al. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Medical oncology (Northwood, London, England). 2015;32(1):362. doi: 10.1007/s12032-014-0362-4Liu X., Zhao Y., Li Y., Zhang J. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects. Artificial cells, nanomedicine, and biotechnology. 2020;48(1):15–27. doi: 10.1080/21691401.2019.1699804Liu X., Zhao Y., Li Y., Zhang J. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects. Artificial cells, nanomedicine, and biotechnology. 2020;48(1):15–27. doi: 10.1080/21691401.2019.1699804Vladimirova L.Yu., Storozhakova A.E., Snezhko T.A., et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46-51. doi: 10.37748/2687-0533-2020-1-2-6Vladimirova L.Yu., Storozhakova A.E., Snezhko T.A., et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46-51. doi: 10.37748/2687-0533-2020-1-2-6

The authors declare that there are no conflicts of interest present.